433 related articles for article (PubMed ID: 30946803)
1. Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure.
Feng J; Li T; Yee R; Yuan Y; Bai C; Cai M; Shi W; Embers M; Brayton C; Saeki H; Gabrielson K; Zhang Y
Discov Med; 2019 Mar; 27(148):125-138. PubMed ID: 30946803
[TBL] [Abstract][Full Text] [Related]
2. Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony
Feng J; Zhang S; Shi W; Zhang Y
Front Microbiol; 2016; 7():1744. PubMed ID: 27867375
[TBL] [Abstract][Full Text] [Related]
3. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline.
Feng J; Auwaerter PG; Zhang Y
PLoS One; 2015; 10(3):e0117207. PubMed ID: 25806811
[TBL] [Abstract][Full Text] [Related]
4. Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime.
Feng J; Weitner M; Shi W; Zhang S; Zhang Y
Front Microbiol; 2016; 7():62. PubMed ID: 26903956
[TBL] [Abstract][Full Text] [Related]
5. Identifying Vancomycin as an Effective Antibiotic for Killing Borrelia burgdorferi.
Wu X; Sharma B; Niles S; O'Connor K; Schilling R; Matluck N; D'Onofrio A; Hu LT; Lewis K
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126963
[No Abstract] [Full Text] [Related]
6. Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.
Sharma B; Brown AV; Matluck NE; Hu LT; Lewis K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4616-24. PubMed ID: 26014929
[TBL] [Abstract][Full Text] [Related]
7. Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31.
Pothineni VR; Potula HSK; Ambati A; Mallajosyula VVA; Sridharan B; Inayathullah M; Ahmed MS; Rajadas J
Sci Rep; 2020 Mar; 10(1):3798. PubMed ID: 32123189
[TBL] [Abstract][Full Text] [Related]
8. Decorin binding proteins of Borrelia burgdorferi promote arthritis development and joint specific post-treatment DNA persistence in mice.
Salo J; Jaatinen A; Söderström M; Viljanen MK; Hytönen J
PLoS One; 2015; 10(3):e0121512. PubMed ID: 25816291
[TBL] [Abstract][Full Text] [Related]
9. Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease.
Weitzner E; McKenna D; Nowakowski J; Scavarda C; Dornbush R; Bittker S; Cooper D; Nadelman RB; Visintainer P; Schwartz I; Wormser GP
Clin Infect Dis; 2015 Dec; 61(12):1800-6. PubMed ID: 26385994
[TBL] [Abstract][Full Text] [Related]
10. Generality of Post-Antimicrobial Treatment Persistence of
Hodzic E; Imai DM; Escobar E
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31308087
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi.
Sapi E; Kaur N; Anyanwu S; Luecke DF; Datar A; Patel S; Rossi M; Stricker RB
Infect Drug Resist; 2011; 4():97-113. PubMed ID: 21753890
[TBL] [Abstract][Full Text] [Related]
12. Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm
Feng J; Zhang S; Shi W; Zubcevik N; Miklossy J; Zhang Y
Front Med (Lausanne); 2017; 4():169. PubMed ID: 29075628
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice.
Moody KD; Adams RL; Barthold SW
Antimicrob Agents Chemother; 1994 Jul; 38(7):1567-72. PubMed ID: 7979290
[TBL] [Abstract][Full Text] [Related]
14. Effect of dapsone alone and in combination with intracellular antibiotics against the biofilm form of B. burgdorferi.
Horowitz RI; Murali K; Gaur G; Freeman PR; Sapi E
BMC Res Notes; 2020 Sep; 13(1):455. PubMed ID: 32993780
[TBL] [Abstract][Full Text] [Related]
15. A Review of Antibiotic-Tolerant Persisters and Their Relevance to Posttreatment Lyme Disease Symptoms.
Baker PJ
Am J Med; 2020 Apr; 133(4):429-431. PubMed ID: 31926865
[TBL] [Abstract][Full Text] [Related]
16. Borreliella burgdorferi Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes.
Cabello FC; Embers ME; Newman SA; Godfrey HP
mBio; 2022 Jun; 13(3):e0344021. PubMed ID: 35467428
[TBL] [Abstract][Full Text] [Related]
17. Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice.
Hodzic E; Imai D; Feng S; Barthold SW
PLoS One; 2014; 9(1):e86907. PubMed ID: 24466286
[TBL] [Abstract][Full Text] [Related]
18. Update of the Swiss guidelines on post-treatment Lyme disease syndrome.
Nemeth J; Bernasconi E; Heininger U; Abbas M; Nadal D; Strahm C; Erb S; Zimmerli S; Furrer H; Delaloye J; Kuntzer T; Altpeter E; Sturzenegger M; Weber R; For The Swiss Society For Infectious Diseases And The Swiss Society For Neurology
Swiss Med Wkly; 2016; 146():w14353. PubMed ID: 27922168
[TBL] [Abstract][Full Text] [Related]
19. Infection with persister forms of Staphylococcus aureus causes a persistent skin infection with more severe lesions in mice: failure to clear the infection by the current standard of care treatment.
Yee R; Yuan Y; Shi W; Brayton C; Tarff A; Feng J; Wang J; Behrens A; Zhang Y
Discov Med; 2019 Jul; 28(151):7-16. PubMed ID: 31465721
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.
Feng J; Wang T; Shi W; Zhang S; Sullivan D; Auwaerter PG; Zhang Y
Emerg Microbes Infect; 2014 Jul; 3(7):e49. PubMed ID: 26038747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
